Vi­iV's long-act­ing HIV in­jectable Cabe­nu­va pre­ferred over Bik­tarvy by 90% of pa­tients in PhI­II tri­al

Last year
Pharma

Mer­ck evolves Keytru­da ad cam­paign, build­ing on pa­tient in­sights and high­light­ing 16 ap­provals

Last year
Pharma
Marketing

FDA ap­proves Ver­ri­ca's skin in­fec­tion treat­ment, en­ters in­to non-bind­ing term sheet for $125M loan

Last year
Pharma
FDA+

Quince buys a rare dis­ease biotech; Heron re­duces head­count

Last year
News Briefing

Pfiz­er ax­es sick­le cell, be­ta tha­lassemia deal with Sy­ros

Last year
Deals

As Am­gen ac­qui­si­tion faces on­go­ing suit, Hori­zon's mid-stage lu­pus tri­al fails

Last year
R&D

In­fin­i­ty and MEI scrap merg­er af­ter un­so­licit­ed bid, lack of share­hold­er sup­port

Last year
Deals

SPAC bust: ARCH, Deer­field and Sec­tion 32 can­cel their $200M life sci­ences bet

Last year
Financing

Bio­Car­dia paus­es en­roll­ment in PhI­II tri­al of heart fail­ure stem cell ther­a­py

Last year
R&D

Up­dat­ed: Roche pays Al­ny­lam $310M cash to part­ner on RNAi can­di­date for heart dis­ease

Last year
Deals

Ko­di­ak ends at­tempt at an Eylea ri­val as its bi­o­log­ic fails two of three PhI­II tri­als

Last year
R&D

Gilead ax­es PhI­II tri­al for CD47 drug in lat­est set­back for $4.9B buy­out

Last year
R&D

Bavar­i­an Nordic scraps RSV vac­cine af­ter PhI­II tri­al miss­es the bar on pre­vent­ing se­vere symp­toms

Last year
R&D

Ex­pand­ing the End­points news­room over­seas, a spe­cial projects hire and our new lead for events

Last year
Editor's note

Phar­ma earn­ings sea­son starts with cor­po­rate prof­its, new CEOs tak­ing cen­ter stage

Last year
Pharma

2023 Women in Bio­phar­ma R&D; Biotech hope­ful for re­bound even as new wave of lay­offs hit; No­var­tis' siR­NA buy­out; and ...

Last year
Weekly

CHMP rec­om­mends against Mi­rati's KRAS ri­val, in fa­vor of Pfiz­er's RSV vac­cine, oth­er drugs

Last year
Pharma
FDA+

Dam­aged Pfiz­er plant re­mains closed as wor­ries mount about short­ages of ster­ile in­jecta­bles

Last year
Manufacturing

Phar­ma brands dom­i­nate ‘new’ TV com­mer­cial list for first half of 2023, ad track­er re­ports

Last year
Pharma
Marketing

Roche with­draws EMA ex­pan­sion ap­pli­ca­tion for can­cer med­i­cine Gazy­varo af­ter lack of 'ro­bust' tri­al meth­ods

Last year
Pharma

Emer­gent’s newest an­thrax vac­cine is now FDA-ap­proved

Last year
FDA+

Lon­za cites biotech fund­ing slow­down as it low­ers sales out­look for the year

Last year
Financing
Manufacturing

Part­nered with Lil­ly, TVM Cap­i­tal and Tillotts fund oral in­flam­ma­to­ry bow­el dis­ease drug with up to $28M

Last year
Financing
Startups

'We sim­ply can­not sus­tain': Idor­sia weighs lay­offs, deals, pipeline trims to bring cost down

Last year
People
First page Previous page 307308309310311312313 Next page Last page
A service from the Financial Times